<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Evaluate anti-interleukin-1β (IL-1β) antibody, canakinumab, in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) in whom <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> may trigger IL-1β-associated <z:mp ids='MP_0001845'>inflammation</z:mp> leading to suppressed insulin secretion and β-cell dysfunction </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This 4-week, parallel-group study randomized 190 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> 2 : 1, canakinumab versus placebo, into the following treatment arms: <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy, <z:chebi fb="0" ids="6801">metformin</z:chebi> + <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, <z:chebi fb="0" ids="6801">metformin</z:chebi> + <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> + thiazolidinedione or insulin ± <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>IGT population (n = 54) was randomized 1 : 1, canakinumab versus placebo </plain></SENT>
<SENT sid="3" pm="."><plain>Primary efficacy assessment was change from baseline in insulin secretion rate (ISR) relative to <z:chebi fb="105" ids="17234">glucose</z:chebi> 0-2 h </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Mean changes from baseline to week 4 in ISR relative to <z:chebi fb="105" ids="17234">glucose</z:chebi> at 0-2 h or other time points were not statistically significant for canakinumab versus placebo across groups </plain></SENT>
<SENT sid="5" pm="."><plain>ISR (relative to <z:chebi fb="105" ids="17234">glucose</z:chebi>) at 0-0.5 h (first-phase insulin secretion) numerically favoured canakinumab versus placebo in insulin-treated patients {difference in mean change from baseline [point estimate (PE)] 3.81 pmol/min/m(2) /mmol/l; p = 0.0525} and in the IGT group (PE 3.92 pmol/min/m(2) /mmol/l; p = 0.1729) </plain></SENT>
<SENT sid="6" pm="."><plain>Mean change from baseline in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> favoured canakinumab in the type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>/<z:chebi fb="0" ids="6801">metformin</z:chebi> group and the IGT group; however, differences were not statistically significant </plain></SENT>
<SENT sid="7" pm="."><plain>Mean change from baseline in peak insulin level and insulin AUC 0-4 h were statistically significantly higher in the canakinumab group in IGT patients </plain></SENT>
<SENT sid="8" pm="."><plain>Canakinumab was well tolerated and consistent with known safety experience </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The trend towards improving ISR relative to <z:chebi fb="105" ids="17234">glucose</z:chebi> 0-0.5 h in patients treated with insulin supports the hypothesis that insulin secretion can be improved by blocking IL-1β </plain></SENT>
</text></document>